Patents Assigned to Chiesi Farmaceutici S.p.A.
  • STABLE PRESSURIZED AEROSOL SOLUTION COMPOSITION OF GLYCOPYRRONIUM BROMIDE AND FORMOTEROL COMBINATION
    Publication number: 20160303045
    Abstract: Aerosol solution compositions intended for use with a pressurized metered dose inhaler, comprising glycopyrronium bromide and formoterol, or a salt thereof or a solvate of said salt, optionally in combination with one or more additional active ingredients, and stabilized by a selected amount of a mineral acid, exhibit improved stability when contained in a can internally coated by a resin comprising a fluorinated ethylene propylene (FEP) polymer.
    Type: Application
    Filed: June 29, 2016
    Publication date: October 20, 2016
    Applicant: CHIESI FARMACEUTICI S.P.A
    Inventors: Sauro BONELLI, Diego Copelli, Massimiliano Dagli Alberi, Francesca Usberti, Enrico Zambelli
  • Melatonin-based formulations for parenteral administration
    Patent number: 9468626
    Abstract: Pharmaceutical formulations comprising nanoparticles of melatonin are useful for the treatment of neonatal brain injury.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: October 18, 2016
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Annamaria Soliani Raschini, Akif Emre Türeli, Eva Marie Prinz
  • Isoxazolidine derivatives
    Patent number: 9469669
    Abstract: Glucocorticosteroids that are derivatives of isoxazolidine are useful as anti-inflammatory and antiallergic compounds of the glucocorticosteroid series.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: October 18, 2016
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventor: Eleonora Ghidini
  • Kinase inhibitors
    Patent number: 9458154
    Abstract: Disclosed are compounds having [1,2,4]triazolo[4,3-a]pyridine groups and pharmaceutically acceptable salts thereof. The compounds are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: October 4, 2016
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Harry Finch, Monique Bodil Van Niel, Chi-Kit Woo
  • PARTICLE SIZE REDUCTION OF AN ANTIMUSCARINIC COMPOUND
    Publication number: 20160279066
    Abstract: A stable crystalline micronized particulate of a glycopyrronium salt may be prepared by suspending the drug in a water-immiscible anti-solvent in which the drug has little or no solubility and micronizing the suspension. The resulting drug particles are physically stable with regard to agglomeration and/or aggregation on storage.
    Type: Application
    Filed: June 10, 2016
    Publication date: September 29, 2016
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Irene PASQUALI, Andrea CASAZZA, Elena LOSI, Mark SAUNDERS
  • Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
    Patent number: 9453013
    Abstract: Compounds of formula (I) defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: September 27, 2016
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Fabio Rancati, Ian Linney, Chris Knight, Wolfgang Schmidt
  • Process for preparing carrier particles for dry powders for inhalation
    Patent number: 9445999
    Abstract: Carrier particles in which at least 60% of the surface is coated with magnesium stearate are useful for preparing dry powder formulations for inhalation.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: September 20, 2016
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Rossella Musa, Daniela Cocconi, Alain Chamayou, Laurence Galet
  • IMPROVED METHOD AND SYSTEM FOR THE ADMINISTRATION OF A PULMONARY SURFACTANT BY ATOMIZATION
    Publication number: 20160263333
    Abstract: The system allows optimizing the dispensing of aerosol medicaments. In particular the system allows the administration of an exogenous pulmonary surfactant to very young patients (e.g. preterm neonates). A catheter (101) conveys atomized surfactant directly to the retropharyngeal region in order to increase efficiency of the medicament administration without being invasive: this is particularly important for very young patients, such as pre-term born neonates suffering from neonatal Respiratory Distress Syndrome (nRDS). The catheter is made of biocompatible flexible material (e.g. plastic material). It is possible to couple the catheter with a rigid scaffolding (e.g. metallic) to increase stiffness of the device and to improve easiness of positioning operations. The delivery of the atomized medicament is done by means of an air blasting technique.
    Type: Application
    Filed: October 16, 2014
    Publication date: September 15, 2016
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Raffaele DELLACA, Ilaria MILESI, Mario DI CECIO, Roger SEWELL, Donal TAYLOR
  • DRY POWDER FORMULATION COMPRISING AN ANTICHOLINERGIC, A CORTICOSTEROID AND A BETA-ADRENERGIC FOR ADMINISTRATION BY INHALATION
    Publication number: 20160263027
    Abstract: Dry powder formulations for inhalation comprising a combination of an anticholinergic, a long-acting beta2-adrenoceptor agonist, and a corticosteroid are useful for the prevention and/or treatment of inflammatory and/or obstructive airways diseases.
    Type: Application
    Filed: May 20, 2016
    Publication date: September 15, 2016
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Irene PASQUALI, Rossella Musa, Francesca Schiaretti, Azita Askey-Sarvar
  • Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
    Patent number: 9440954
    Abstract: Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols according to formula (I) are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme.
    Type: Grant
    Filed: June 4, 2013
    Date of Patent: September 13, 2016
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Elisabetta Armani, Carmelida Capaldi, Laura Carzaniga, Oriana Esposito
  • Kinase inhibitors
    Patent number: 9440974
    Abstract: Compounds of formula (I) described herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: September 13, 2016
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Lilian Alcaraz, Christopher Hurley, Andrew Peter Cridland, Andrew Stephen Robert Jennings
  • Process for the preparation of a PDE4 inhibitor
    Patent number: 9434691
    Abstract: The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: September 6, 2016
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Alessandro Falchi, Emilio Lutero, Emanuele Ferrari, Fausto Pivetti, Rocco Bussolati, Edoardo Mariani, Orsola Vecchi, Erhard Bappert, Caterina Ventrici
  • NOVEL COMPOUNDS
    Publication number: 20160251362
    Abstract: Compounds of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for treating diseases and conditions in which HNE is implicated.
    Type: Application
    Filed: May 10, 2016
    Publication date: September 1, 2016
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: LILIAN ALCARAZ, ROBERT ANDREW HEALD, JONATHAN MARK SUTTON, ELISABETTA ARMANI, CARMELIDA CAPALDI
  • Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
    Patent number: 9427376
    Abstract: Cohesive high-dosage strength micronized active ingredients may be dispersed in dry powder formulations for inhalation comprising carrier particles, by use of the apparatus described herein.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: August 30, 2016
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Claudio Cafiero, Federico Tosini
  • COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
    Publication number: 20160235734
    Abstract: Compounds of formula I, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating broncho-obstructive and inflammatory diseases.
    Type: Application
    Filed: February 10, 2016
    Publication date: August 18, 2016
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Fabio RANCATI, Andrea RIZZI, Laura CARZANIGA, Ian LINNEY, Chris KNIGHT, Wolfgang SCHMIDT
  • KINASE INHIBITORS
    Publication number: 20160229852
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Application
    Filed: April 18, 2016
    Publication date: August 11, 2016
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Monique Bodil VAN NIEL, Nicholas Charles RAY, Lilian ALCARAZ, Terry Aaron PANCHAL, Andrew Stephen Robert JENNINGS, Elisabetta ARMANI, Andrew Peter CRIDLAND, Christopher HURLEY
  • Compounds
    Patent number: 9409870
    Abstract: Compounds of formula (I) described herein are imidazolone derivatives having human neutrophil elastase (HNE) inhibitory properties and are useful for the treatment of diseases and conditions in which HNE is implicated.
    Type: Grant
    Filed: November 27, 2015
    Date of Patent: August 9, 2016
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Elisabetta Armani, Carmelida Capaldi, Jonathan Mark Sutton, Robert Andrew Heald
  • Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
    Patent number: 9402825
    Abstract: Dry powder formulations for inhalation comprising a combination of an anticholinergic, a long-acting beta2-adrenoceptor agonist, and a corticosteroid are useful for the prevention and/or treatment of inflammatory and/or obstructive airways diseases.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: August 2, 2016
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Irene Pasquali, Rossella Musa, Francesca Schiaretti, Azita Askey-Sarvar
  • Use of pulmonary surfactants in lung transplantation and methods thereof
    Patent number: 9402603
    Abstract: The present invention concerns a method of treating an advanced lung disease in a patient in need thereof by lung transplantation.
    Type: Grant
    Filed: January 8, 2013
    Date of Patent: August 2, 2016
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Federico Bianco, Roberta Razzetti, Patrizio Vitulo, Alessandro Bertani
  • Particle size reduction of an antimuscarinic compound
    Patent number: 9393202
    Abstract: A stable crystalline micronized particulate of a glycopyrronium salt may be prepared by suspending the drug in a water-immiscible anti-solvent in which the drug has little or no solubility and micronizing the suspension. The resulting drug particles are physically stable with regard to agglomeration and/or aggregation on storage.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: July 19, 2016
    Assignee: CHIESI FARMACEUTICI S.p.A
    Inventors: Irene Pasquali, Andrea Casazza, Elena Losi, Mark Saunders